On January 6, 2017 Atreca, Inc., a biotechnology company focused on developing novel therapeutics based on a deep understanding of the human immune response, reported that Tito A. Serafini, Ph.D., Atreca’s President, Chief Executive Officer, and CoFounder, will participate in a panel discussion on immuno-oncology (IO) during the 9th Annual Biotech Showcase Conference on Wednesday, January 11, 2017, at 11:00a.m. Pacific Time (Press release, Atreca, JAN 6, 2017, View Source [SID1234522958]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The panel, titled "The Overflowing IO Buffet: Next Gen IO Antibodies, Oncolytic Viruses, Bispecifics, Adoptive Cell Therapies and Oral Immunometabolism / Immuno-Epigenetic Agents," will be held at the Hilton San Francisco Union Square in Continental Room 2.